Combination therapy for RCC increases response rate

August 17, 2007

A combination of interferon alfa-2b and sorafenib (Nexavar) works better than does either drug alone in improving response in patients with renal cell carcinoma, according to a pilot study led by researchers from the Duke Comprehensive Cancer Center, Durham, NC.

A combination of interferon alfa-2b and sorafenib (Nexavar) works better than does either drug alone in improving response in patients with renal cell carcinoma, according to a pilot study led by researchers from the Duke Comprehensive Cancer Center, Durham, NC.

Used in combination, the drugs led to significant tumor shrinkage in 33% of the 40 patients who participated in the study, and two of the patients had complete responses, the researchers reported (J Clin Oncol 2007; 25:3288-95). Study participants all had stage IV renal cell carcinoma.

Researchers gave study patients sorafenib in a pill form twice daily and interferon alfa-2b via injection three times a week for 8-week cycles. If the patient’s tumor had not grown or had shrunk after 8 weeks, the cycle would be repeated after a 2-week break until the tumors disappeared or until the cancer got worse.

“We found that by combining a drug that enlists the immune system’s help in combating cancer with one that cuts off a tumor’s blood supply, we could substantially increase patients’ response rates to treatment,” said lead investigator Jared Gollob, MD. “Most tumors that respond to either therapy alone begin growing again after about 5 or 6 months. By using interferon alfa-2b and sorafenib in combination, we not only increased the response rate, but found we could double the amount of time that these patients could survive without their tumors growing.”

A multi-site confirmatory trial is planned to determine whether patients show additional progress with increasing doses of sorafenib alone after achieving maximum tumor shrinkage with the dual therapy, Dr. Gollob said.

Related Content:

News